Publications

 

2020

85 Sun J, Muz B, Alhallak K, Markovic M, Gurley S, Wang Z, Guenthner N, Wasden K, Fiala M, King J, Kohnen D, Salama NN, Vij R, Azab AK. Targeting CD47 as a novel immunotherapy for multiple myeloma. Cancers. 2020 Feb;12(2):305. Pubmed

2019

84 Imperio D, Muz B, Azab AK, Fallarini S, Lombardi G, Panza L. A short and convenient synthesis of closo‐dodecaborate sugar conjugates. European Journal of Organic Chemistry. Article
83 Muz B, Bandara N, Mpoy C, Sun J, Alhallak K, Azab F, Rogers BE, Azab AK. CXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of Waldenström Macroglobulinemia. Cancer Biology & Therapy. 2019 Oct 3:1-9. PubMed
82 Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. American journal of hematology. 2019 Nov;94(11):1244-53. PubMed
81 Muz B, Azab F, Fiala M, King J, Kohnen D, Fogler WE, Smith T, Magnani JL, Vij R, Azab AK. Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy. Blood cancer journal. 2019 Aug 20;9(9):1-6. PubMed
80 Luderer MJ, Muz B, Alhallak K, Sun J, Wasden K, Guenthner N, de la Puente P, Federico C, Azab AK. Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy. Pharmaceutical Research. 2019 Oct 1;36(10):144. PubMed
79 Muz B, Buggio M, Azab F, de la Puente P, Fiala M, Padval MV, Weaver DT, Pachter JA, Vij R, Azab AK. PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma. Haematologica. 2019 Jul;104(7):e310. PubMed

2018

78 de la Puente P, Fettig N, Luderer MJ, Jin A, Shah S, Muz B, Kapoor V, Goddu SM, Salama NN, Tsien C, Thotala D, Shoghi K, Rogers B, Azab AK. Injectable Hydrogels for Localized Chemo- and Radio-Therapy in Brain Tumors. Journal of pharmaceutical sciences. 2018 Mar 1;107(3):922-33. PubMed
77 de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J. Vij R, Azab AK. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. Journal of Controlled Release. 2018 Jan 28;270:158-76. PubMed

2017

76 Weisberg EL, Sattler M, Azab AK, Eulberg D, Kruschinski A, Manley PW, Stone R, Griffin JD. Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget. 2017 Dec 15;8(66):109973. PubMed
75 Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J. Cxcl12 and Cxcr7 are relevant targets to reverse cell adhesion‐mediated drug resistance in multiple myeloma. British journal of Haematology. 2017 Oct 1;179(1):36-49. PubMed
74 Muz B, Azab F, de la Puente P, Landesman Y, Azab AK. Selinexor overcomes hypoxia-induced drug resistance in multiple myeloma. Translational Oncology. 2017 Aug 1;10(4):632-40. PubMed
73 Muz B, Kusdono HD, Azab F, de la Puente P, Federico C, Fiala M, Vij R, Salama NN, Azab AK. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance. Leukemia & Lymphoma. 2017 Dec 2;58(12):2916-25. PubMed
72 de la Puente P, Fettig N, Luderer MJ, Jin A, Shah S, Muz B, Kapoor V, Goddu SM, Salama NN, Tsien C, Thotala D, Shoghi K, Rogers B, Azab AK. Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors. Journal of Pharmaceutical Sciences. 2017 Nov 21. PubMed
71 de la Puente P, Azab AK. Nanoparticle delivery systems, general approaches and their implementation in Multiple Myeloma. European Journal of Haematology. 2017 Feb 1. PubMed
70 Burwick N, Zhang MY, de la Puente P, Azab AK, Hyun TS, Ruiz-Gutierrez M, Sanchez-Bonilla M, Nakamura T, Delrow JJ, MacKay VL, Shimamura A. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leukemia Research. 2017 Apr 30;55:23-32. PubMed
69 Imai T*, Muz B*, Yeh CH, Yao J, Zhang R, Azab AK^, Wang L^. Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy. Cancer Biology & Therapy. 2017 Feb 1;18(2):101-5. PubMed

2016

68 Ordikhani F, Erdem Arslan M, Marcelo R, Sahin I, Grigsby P, Schwarz JK, Azab AK. Drug delivery approaches for the treatment of cervical cancer. Pharmaceutics. 2016 Jul 20;8(3):23. PubMed
67 de la Puente P, Quan N, Hoo RS, Muz B, Gilson RC, Luderer M, King J, Achilefu S, Salama NN, Vij R, Azab AK. Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma. Haematologica. 2016 Jul 1;101(7):e307-11. PubMed
66 Luderer MJ, Muz B, de la Puente P, Chavalmane S, Kapoor V, Marcelo R, Biswas P, Thotala D, Rogers B, Azab AK. A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma. Pharmaceutical Research. 2016 Oct 1;33(10):2530-9. PubMed
65 de la Puente P, and Azab AK. 3D tissue engineered bone marrow: what does this mean for the treatment of multiple myeloma? Future Oncology. 2016. (13):1545-7. PubMed
64 Fulciniti M, Amodio N, Cea M, Maiso P, Azab AK. Biological insights into myeloma and other B cell malignancies. BioMed Research International. 2016 Feb 16;2016. PubMed
63 de La Puente P, Muz B, Jin A, Azab F, Luderer M, Salama NN, Azab AK. MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma. Blood Cancer Journal. 2016 Feb 1;6(2):e399. PubMed
62 Muz B, Puente P, Azab F, Luderer MJ, King J, Vij R, Azab AK. A CD138‐independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma. British Journal of Haematology. 2016 Apr 1;173(1):70-81. PubMed
61 Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK. Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Design, Development and Therapy. 2016;10:217. PubMed
60 de la Puente P, Azab F, Muz B, Luderer M, Arbiser J, Azab AK. Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma. Leukemia & Lymphoma. 2016 Jul 2;57(7):1677-86. PubMed

2015

59 Luderer MJ, de la Puente P, Azab AK. Advancements in tumor targeting strategies for boron neutron capture therapy. Pharmaceutical Research. 2015 Sep 1;32(9):2824-36. PubMed
58 Kapoor V, Khudanyan A, de la Puente P, Campian J, Hallahan DE, Azab AK, Thotala D. Stem cell transfusion restores immune function in radiation-induced lymphopenic C57BL/6 mice. Cancer Research. 2015 Sep 1;75(17):3442-5. PubMed
57 de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, Achilefu S, Vij R, Azab AK. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials. 2015 Dec 31;73:70-84. PubMed
56 de la Puente P, Weisberg E, Muz B, Nonami A, Luderer M, Stone RM, Melo JV, Griffin JD, Azab AK. Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. Leukemia Research. 2015 Nov 30;39(11):1299-308. PubMed
55 Muz B, Azab F, de la Puente P, Rollins S, Alvarez R, Kawar Z, Azab AK. Inhibition of P-Selectin and PSGL-1 using humanized monoclonal antibodies increases the sensitivity of multiple myeloma cells to Bortezomib. BioMed Research International. 2015 Oct 11;2015. PubMed
54 Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia. 2015;3:83. PubMed
53 Muz B, de la Puente P, Azab F, Ghobrial IM, Azab AK. Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenström Macroglobulinemia. Molecular Cancer Research. 2015 Feb 1;13(2):263-72. PubMed
52 Abraham J, Salama NN, Azab AK. The role of P-glycoprotein in drug resistance in multiple myeloma. Leukemia & Lymphoma. 2015 Jan 2;56(1):26-33. PubMed

2014

51 Sahin I, Moschetta M, Mishima Y, Glavey SV, Tsang B, Azab F, Manier S, Zhang Y, Maiso P, Sacco A, Azab AK, Roccaro AM, Ghobrial IM. Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination. Blood Cancer Journal. 2014 Apr;4(4):e204. PubMed
50 Lu ZH, Kaliberov S, Zhang J, Muz B, Azab AK, Sohn RE, Kaliberova L, Du Y, Curiel DT, Arbeit JM. The myeloid binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting. Laboratory Investigation. 2014 Aug;94(8):881. PubMed
49 Azab F, Vali S, Potter N, Abraham J, Muz B, De La Puente P, Abbasi T, Vij R, Azab AK. PI3K-Alpha Plays A Major Role In Multiple Myeloma and Its Inhibition With BYL917 Decreases Proliferation, Synergizes With Other Therapies and Overcomes Stroma-Induced Resistance. Blood. 2013 Nov 15;122(21):3215-. PubMed
48 de la Puente P, Muz B, Azab F, Luderer M, Azab AK. Molecularly targeted therapies in multiple myeloma. Leukemia Research and Treatment. 2014 Apr 16;2014. PubMed
47 de la Puente P, Azab AK. Delivery systems for brachytherapy. Journal of Controlled Release. 2014 Oct 28;192:19-28. PubMed
46 Sahin I, Azab F, Mishima Y, Moschetta M, Tsang B, Glavey SV, Manier S, Zhang Y, Sacco A, Roccaro AM, Azab AK, Ghobrial IM. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan‐class I PI3K inhibitor, buparlisib. American Journal of Hematology. 2014 Nov 1;89(11):1030-6. PubMed
45 Azab AK, Sahin I, Azab F, Moschetta M, Mishima Y, Burwick N, Zimmermann J, Romagnoli B, Patel K, Chevalier E, Roccaro AM, Ghobrial IM. CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. Blood. 2014 Sep 18;124(12):1905-14. PubMed
44 Muz B, de la Puente P, Azab F, Luderer M, Azab AK. The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies. Molecular Cancer Research. 2014 Oct 1;12(10):1347-54. PubMed
43 Muz B, De La Puente P, Azab F, Luderer M, Azab AK. Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. Blood Cancer Journal. 2014 Dec;4(12):e262. PubMed

2013

42 Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM. BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression. The Journal of Clinical Investigation. 2013 Apr 1;123(4):1542. PubMed
41 Liu Y, Quang P, Braggio E, Ngo H, Badalian-Very G, Flores L, Zhang Y, Sacco A, Maiso P, Azab AK, Azab F, Carrasco R, Rollins BJ, Roccaro AM, Ghobrial IM. Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma. PloS One. 2013 Jun 13;8(6):e66982. PubMed
40 Azab AK, Weisberg E, Sahin I, Liu F, Awwad R, Azab F, Liu Q, Griffin JD, Ghobrial IM. The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression. Leukemia. 2013 Apr 1;27(4):961-5. PubMed
39 Azab F, Muz B, de la Puente P, Salama NN and Azab AK. Monograph: NPV-BKM-120. Drugs of the Future. 2013. 38(2): 73
38 de la Puente P, Muz B, Azab F, Azab AK. Cell trafficking of endothelial progenitor cells in tumor progression. Clinical Cancer Research. 2013 Jul 1;19(13):3360-8. PubMed
37 de la Puente P, Azab AK. Contemporary drug therapies for multiple myeloma. Drugs of Today (Barcelona, Spain). 2013 Sep;49(9):563-73. PubMed

2012

36 Roccaro AM, Sacco A, Jia X, Banwait R, Maiso P, Azab F, Flores L, Manier S, Azab AK, Ghobrial IM. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. Clinical Cancer Research. 2012 Dec 15;18(24):6609-22. PubMed
35 Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood. 2012 Dec 13;120(25):5002-13. PubMed
34 Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM. LNA-mediated anti–miR-155 silencing in low-grade B-cell lymphomas. Blood. 2012 Aug 23;120(8):1678-86. PubMed
33 Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, Patton JT, Maiso P, Monrose V, Sacco A, Ngo HT, Lin CP, Magnani JL,  Kung AL, Letai A, Carrasco R, Roccaro AM and Ghobrial IM. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012 Feb 9;119(6):1468-78. PubMed
32 Weisberg E*, Azab AK*, Manley PW, Kung AL, Christie AL, Bronson R, Ghobrial IM, Griffin JD. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib: Potentiation of nilotinib by CXCR4 antagonist. Leukemia. 2012 May;26(5):985. PubMed
31 Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012 Jun 14;119(24):5782-94. PubMed

2011

30 Azab F*, Azab AK*, Maiso P, Calimeri T, Flores LM, Liu Y, Quang P, Roccaro AM, Sacco A, Ngo HT, Zhang Y. Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom’s macroglobulinemia. Clinical Cancer Research. 2011 Oct 18:clincanres-0111. PubMed
29 Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, Zhang Y, Azab F, Ngo HT, Issa GC, Quang P, Roccaro AM, Ghobrial IM. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom’s Macroglobulinemia. Clinical Cancer Research. 2011 Apr 1;17(7):1753-64. PubMed
28 Sacco A, Maiso P, Azab A, Azab F, Zhang Y, Liu Y, Ngo HT, Morgan B, Quang P, Issa G, Ghobrial IM, Roccaro AM. Key Role of MicroRNAs in Waldenström’s Macroglobulinemia Pathogenesis. Clinical Lymphoma Myeloma and Leukemia. 2011 Feb 28;11(1):109-11. PubMed
27 Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa G, Roccaro A. The Bone Marrow Niche in Waldenström’s Macroglobulinemia. Clinical Lymphoma Myeloma and Leukemia. 2011 Feb 28;11(1):118-20. PubMed
26 Neri P, Ren L, Azab AK, Brentnall M, Gratton K, Klimowicz AC, Lin C, Duggan P, Tassone P, Mansoor A, Stewart DA, Boise LH, Ghobrial IM, Bahlis NsJ. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood. 2011 Jun 9;117(23):6202-13. PubMed
25 Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, Roccaro A, Rommel C, Ghobrial IM Defining the role of TORC1/2 in multiple myeloma. Blood. 2011 Dec 22;118(26):6860-70. PubMed
24 Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa GC, Leleu X, Roccaro AM. Targeting the bone marrow in Waldenstrom macroglobulinemia. Clinical Lymphoma Myeloma and Leukemia. 2011 Jun 30;11:S65-9. PubMed
23 Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, Roccaro AM, Ghobrial IM. FGFR3 is overexpressed Waldenström macroglobulinemia and its inhibition by dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clinical Cancer Research. 2011 Jul 1;17(13):4389-99. PubMed

2010

22 Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C, Ghobrial IM. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood. 2010 Jan 21;115(3):559-69. PubMed
21 Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström’s macroglobulinemia. Clinical Cancer Research. 2010 Feb 1;16(3):1033-41. PubMed
20 Roccaro AM, Sacco A, Aujay M, Ngo HT, Azab AK, Azab F, Quang P, Maiso P, Runnels J, Anderson KC, Demo S, Ghobrial IM. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenström macroglobulinemia. Blood. 2010 May 20;115(20):4051-60. PubMed
19 Roccaro AM, Sacco A, Jia X, Azab AK, Maiso P, Ngo HT, Azab F, Runnels J, Quang P, Ghobrial IM. microRNA-dependent modulation of histone acetylation in Waldenström macroglobulinemia. Blood. 2010 Sep 2;116(9):1506-14. PubMed
18 Khazanov E, Emmanuel N, Azab AK, Barenholz Y, Yavin E, Rubinstein A. Specific Detection of Gastric α-Antitrypsin by Immobilized Trypsin on PolyHEMA Films. Molecular Pharmaceutics. 2010 Jul 8;7(4):944-52. PubMed
17 Runnels JM, Carlson AL, Pitsillides C, Thompson B, Wu J, Spencer JA, Kohler JM, Azab AK, Moreau AS, Rodig SJ, Kung AL, Anderson KC, Ghobrial IM, Lin CP. Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. Journal of Biomedical Optics. 2011 Jan 1;16(1):011006-. PubMed

2009

16 Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, and Ghobrial IM. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood. 2009 Apr 30;113(18):4391-402. PubMed
15 Ghobrial IM*, Leleu X*, Azab AK*, Runnels J*, Jia X*, Ngo H*, Melhem M*, Azab F*, Sacco A*, Quang P*, Burwick N*, Moreau AS*, Husu E*, Farag M*, Roccaro A*. Novel Therapeutic Agents in Waldenström’s Macroglobulinemia. Clinical Lymphoma and Myeloma. 2009 Mar 1;9(1):84-6. PubMed
14 Roccaro AM, Sacco A, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem M, Moreau AS, Ghobrial IM. Role of proteasome inhibition in Waldenström’s macroglobulinemia. Clinical Lymphoma and Myeloma. 2009 Mar 1;9(1):94-6. PubMed
13 Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, and Ghobrial IM. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009 Jun 25;113(26):6669-80. PubMed
12 Nadler-Milbauer M, Azab AK, Kleinstern J, Barenholz Y, Rubinstein A. In vitro and in vivo analysis of pulsatile biodegradation of mucoadhesive hydrogels. Journal of Drug Delivery Science and Technology. 2009 Jan 1;19(4):247-55.
11 Ngo HT, Azab AK, Farag M, Jia X, Melhem MM, Runnels J, Roccaro AM, Azab F, Sacco A, Leleu X, Anderson KC, Ghobrial IM. Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clinical Cancer Research. 2009 Oct 1;15(19):6035-41. PubMed
10 Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Beatriz O, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo T, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ, Anderson KC, Kung AL, Lin CP, and Ghobrial IM. The CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009 Apr 30;113(18):4341-51. PubMed
9 Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, Roccaro AM, Ngo HT, Melhem MR, Sacco A, Jia X, Anderson KC, Lin CP, Rollins BJ, Ghobrial IM. RhoA and Rac1 GTPases play major and differential roles in stromal cell–derived factor-1–induced cell adhesion and chemotaxis in multiple myeloma. Blood. 2009 Jul 16;114(3):619-29. PubMed

2008

8 Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, Treon SP, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM.. Dual targeting of the proteasome regulates survival and homing in Waldenström macroglobulinemia. Blood. 2008 May 1;111(9):4752-63. PubMed
7 Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melhem MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC and Ghobrial IM.. Targeting NF-κB in Waldenstrom macroglobulinemia. Blood. 2008 May 15;111(10):5068-77. PubMed
6 Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, Moreau AS, Burwick N, Azab AK, Roccaro A, Azab F, Sacco A, Farag M, Sackstein R and Ghobrial IM. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood. 2008 Jul 1;112(1):150-8. PubMed
5 Azab AK, Kleinstern J, Srebnik M, Rubinstein A. The metastatic stage-dependent mucosal expression of sialic acid is a potential marker for targeting colon cancer with cationic polymers. Pharmaceutical Research. 2008 Feb 1;25(2):379-86. PubMed

2007

4 Azab AK, Doviner V, Orkin B, Kleinstern J, Srebnik M, Nissan A, Rubinstein A. Biocompatibility evaluation of crosslinked chitosan hydrogels after subcutaneous and intraperitoneal implantation in the rat. Journal of Biomedical Materials Research Part A. 2007 Nov 1;83(2):414-22. PubMed
3 Azab AK, Kleinstern J, Doviner V, Orkin B, Srebnik M, Nissan A, Rubinstein A. Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 131 I-norcholesterol. Journal of Controlled Release. 2007 Nov 6;123(2):116-22. PubMed

2006

2 Azab AK, Orkin B, Doviner V, Nissan A, Klein M, Srebnik M, Rubinstein A. Crosslinked chitosan implants as potential degradable devices for brachytherapy: in vitro and in vivo analysis. Journal of Controlled Release. 2006 Apr 10;111(3):281-9. PubMed

2005

1 Azab AK, Srebnik M, Doviner V, Rubinstein A. Targeting normal and neoplastic tissues in the rat jejunum and colon with boronated, cationic acrylamide copolymers. Journal of Controlled Release. 2005 Aug 18;106(1):14-25. PubMed

* These authors of equal contribution
^ Corresponding authors

 

Chapters in Books

1 Azab AK, Abu Ali H and Srebnik M. Boron neutron capture therapy. In: Abu Ali H., Dembitsky V., Srebnik M. (Editors), Contemporary Aspects of Boron: Chemistry and Biological Applications. Amsterdam, Elsevier, 2005. p. 337-366.